Ascendis Pharma A/S Announces Upcoming Investor Presentations in August
Ascendis Pharma A/S (Nasdaq: ASND) announced participation in two investor conferences this August, providing updates on its pipeline and company overview. The key events are:
- Wedbush PacGrow Healthcare Conference on August 11, 2021, at 9:10 a.m. ET (Virtual)
- Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 11:00 a.m. ET (Virtual)
Live webcasts will be accessible on the Ascendis Pharma website, with replays available for 30 days post-event. The company focuses on innovative therapies addressing unmet medical needs.
- None.
- None.
COPENHAGEN, Denmark, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create new product candidates that address unmet medical needs, today announced that the company will participate in two upcoming investor conferences in August. Company executives will provide a business overview and update on the company’s pipeline programs.
Details
| Event | 2021 Wedbush PacGrow Healthcare Conference |
| Location | Virtual |
| Date | Wednesday, August 11, 2021 |
| Time | 9:10 a.m. Eastern Time |
| Event | Canaccord Genuity 41st Annual Growth Conference |
| Location | Virtual |
| Date | Thursday, August 12, 2021 |
| Time | 11:00 a.m. Eastern Time |
A live webcast of the presentations will be available in the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the events for 30 days.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.
Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates and one oncology product candidate in clinical development. The company continues to expand into additional therapeutic areas to address unmet patient needs.
Ascendis is headquartered in Copenhagen, Denmark, with additional facilities in Heidelberg and Berlin, Germany, in Palo Alto and Redwood City, California, and in Princeton, New Jersey.
Please visit www.ascendispharma.com (for global information) or www.ascendispharma.us (for U.S. information).
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Ascendis’ ability to apply its platform technology to build a leading, fully integrated biopharma company, (i) Ascendis’ product pipeline and expansion into additional therapeutic areas and (ii) Ascendis’ expectations regarding its ability to utilize its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: unforeseen safety or efficacy results in its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development and potential commercialization of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs, selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; Ascendis’ ability to obtain additional funding, if needed, to support its business activities and the effects on its business from the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on March 10, 2021 and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group. © August 2021 Ascendis Pharma A/S.
| Investor contacts: Tim Lee Ascendis Pharma (650) 374-6343 tle@ascendispharma.com |
| Patti Bank Westwicke Partners (415) 513-1284 patti.bank@westwicke.com ir@ascendispharma.com |
FAQ
What are the details of Ascendis Pharma's participation in investor conferences in August 2021?
Where can I watch the presentations from Ascendis Pharma's investor conferences?
What topics will Ascendis Pharma cover during its investor conference presentations?
What is the significance of Ascendis Pharma's upcoming investor conferences?
What is the stock symbol for Ascendis Pharma?
